DIABETON MB IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS AND PREVENTION OF ITS LATE COMPLICATIONS


如何引用文章

全文:

详细

The article is dedicated to the role of sulfonylureas (SU), primarily gliclazide (Diabeton MR) in the treatment of type 2 diabetes mellitus (DM2), discusses their effects on the cardiovascular system. Data supporting the benefits of gliclazide in front of so-called old SU (glibenclamide, etc.) are presented. It is shown that in addition to pronounced hypoglycemic action gliclazide has an antioxidant property, ability to prevent development of micro- and macrovascular complications of DM2, including myocardial infarction and stroke. The antioxidant properties, the lack of effect on apoptosis provide gentle action of this drug on β-cells, that is also a undeniable advantage of gliclazide.

参考

  1. Guillasseau PJ, Greb W. 24-hour glycemic profile in type 2 diabetic patient treated with gliclazide modified realease once daily. Diabete Metab 2001;27:133-37.
  2. Salas M, Caro JJ. Are hypoglycemia and other adverse effects similar among sulphonylureas. Advers Drug React Toxicol Rev 2002;21:205-17.
  3. Drouin P. Diamicron MR study group. J Diabet Complic 2000;14:185-91.
  4. The ADVANCE collaborative group. N Engl J Med 2008;358:2560-72.
  5. Schernthaner G, Di Mario U, Grimaldi A. Glucose control in type 2 diabetes. Diamicron MR versus glimeprirde. Diabetologia 2003;45(suppl. 2):A281.
  6. Ashcroft FM, Gribble FM. Sulfonilurea stimulation of insulin secretion: lessons from studies of cloned channels. J Diabet Compl 2000;12:2182-8.
  7. Seino S, Miki T. КATP channels as metabolitic sensors: protective roles against acute metabolic changes. Medicographia 2005;27(4):3007-10.
  8. Pogatsa G, et al. Effects of Glimepiride and Gliclazide on Cardiac Arrhytmias in Patient with type 2 diabetes and cardiac insufficiency. Diabetes 2001;50(suppl.):A128.
  9. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004;18:113-19.
  10. Gribble FM, Tuccker SJ, Seino S, Ashcroft FM. Tissue specifity of sulfonilureas: studies on cloned cardiac and β-cell KATP channels. Diabetes 1998;47:1412-18.
  11. Ashcroft FM, Gribble FM. ATP sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999;42:903-19.
  12. O'Brien RC, Luo M, Balazs N, Mercuri J. In-vitro and in-vivo antioxidant properties of gliclazide. J Diabet Complic 2000;14:201-06.
  13. Fava D, Cassone-Faldetta M, et al. Gliclazide improves antioxidant status and nitric oxide-mediated vasodilatation in type 2 diabetes. Diabetic Med 2002;19:752-3.
  14. Alvarsson M, Sundkvista G, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 DM. Diabetes Care 2003;26:2331-37.
  15. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004;279:42351-54.
  16. Iwakura T, Fujimoto S, et al. Sustained enhancement of Ca2+ influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 2000;271:422-28.
  17. Kimoto K, Suzuki K, et al. Cliclazide protects pancreatic β-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003;303:112-19.
  18. Noda Y, Mori A, et al. Cliclazide scavenges hydroxyl and superoxide radicals: an electron spin resonance study. Metabolism 2000;49(suppl.):14-26.
  19. Satoh J, Takahashi K. Secondary sulfonylurea failure. Diabet Res Clin Pract 2005;70:291-97.
  20. Florkowski CM, Richardson MR, Le Guen C, et al. Effect of gliclazide on parameters of hemostasis, lipid thromboxane B2 peroxides and fluorescent IgG in type 2 diabetes mellitus. Diabetologia 1988;31:490A.
  21. Johnsen SP, Monster TBM, Olsen ML, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006;13(2):134-40.
  22. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;doi: 10.1093/eurheartj/ehr077.
  23. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and ardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabet Res Clin Pract 2009;86:247-53.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2011